Despite the still elusive mechanism of action, the sigma-2 receptor, which is overexpressed in several tumors, is emerging as a target for cancer treatment, with breast and lung cancer cells characterized as responsive to sigma-2 receptor-mediated cytotoxic action [2–7]. This evidence concerns the gene TMEM97 and lung carcinoma.